- 作者: Mukesh Kumar, Akansha Jalota, Sushil Kumar Sahu & Shabirul Haque
- 作者服務機構: 1.Center of Autoimmune Musculoskeletal and Hematopoietic Disease, Feinstein Institute for Medical Research, Northwell Health, 350 Community Drive, Manhasset, NY, 11030, USA 2.Department of Inflammation and Immunity, Lerner Research Institute, Cleveland, OH, USA 3.Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, 19107, USA 4.Department of Zoology, Siksha-Bhavana, Visva-Bharati, Santiniketan, West Bengal, India
- 中文摘要:
- 英文摘要:
The developments of antibodies for cancer therapeutics have made remarkable success in recent years. There are multiple factors contributing to the success of the biological molecule including origin of the antibody, isotype, affinity, avidity and mechanism of action. With better understanding of mechanism of cancer progression and immune manipulation, recombinant formats of antibodies are used to develop therapeutic modalities for manipulating the immune cells of patients by targeting specific molecules to control the disease. These molecules have been successful in minimizing the side effects instead caused by small molecules or systemic chemotherapy but because of the developing therapeutic resistance against these antibodies, combination therapy is thought to be the best bet for patient care. Here, in this review, we have discussed different aspects of antibodies in cancer therapy affecting their efficacy and mechanism of resistance with some relevant examples of the most studied molecules approved by the US FDA. - 中文關鍵字:
- 英文關鍵字: Antibody, Cancer therapy, Antibody–drug conjugate (ADC), Immune-modulation, Chemo-resistance